Axonal Degeneration in Guillain–Barré Syndrome: A Reappraisal

α
Jose Berciano
Jose Berciano
α Universidad de Cantabria Universidad de Cantabria

Send Message

To: Author

Axonal Degeneration in Guillain–Barré Syndrome: A Reappraisal

Article Fingerprint

ReserarchID

WNG0X

Axonal Degeneration in Guillain–Barré Syndrome: A Reappraisal Banner

AI TAKEAWAY

Connecting with the Eternal Ground
  • English
  • Afrikaans
  • Albanian
  • Amharic
  • Arabic
  • Armenian
  • Azerbaijani
  • Basque
  • Belarusian
  • Bengali
  • Bosnian
  • Bulgarian
  • Catalan
  • Cebuano
  • Chichewa
  • Chinese (Simplified)
  • Chinese (Traditional)
  • Corsican
  • Croatian
  • Czech
  • Danish
  • Dutch
  • Esperanto
  • Estonian
  • Filipino
  • Finnish
  • French
  • Frisian
  • Galician
  • Georgian
  • German
  • Greek
  • Gujarati
  • Haitian Creole
  • Hausa
  • Hawaiian
  • Hebrew
  • Hindi
  • Hmong
  • Hungarian
  • Icelandic
  • Igbo
  • Indonesian
  • Irish
  • Italian
  • Japanese
  • Javanese
  • Kannada
  • Kazakh
  • Khmer
  • Korean
  • Kurdish (Kurmanji)
  • Kyrgyz
  • Lao
  • Latin
  • Latvian
  • Lithuanian
  • Luxembourgish
  • Macedonian
  • Malagasy
  • Malay
  • Malayalam
  • Maltese
  • Maori
  • Marathi
  • Mongolian
  • Myanmar (Burmese)
  • Nepali
  • Norwegian
  • Pashto
  • Persian
  • Polish
  • Portuguese
  • Punjabi
  • Romanian
  • Russian
  • Samoan
  • Scots Gaelic
  • Serbian
  • Sesotho
  • Shona
  • Sindhi
  • Sinhala
  • Slovak
  • Slovenian
  • Somali
  • Spanish
  • Sundanese
  • Swahili
  • Swedish
  • Tajik
  • Tamil
  • Telugu
  • Thai
  • Turkish
  • Ukrainian
  • Urdu
  • Uzbek
  • Vietnamese
  • Welsh
  • Xhosa
  • Yiddish
  • Yoruba
  • Zulu

Abstract

The aim of this review was to analyse the pathophysiology of axonal degeneration in Guillain-Barré syndrome (GBS) with emphasis on early stages (≤ 10 days after onset). An overview of experimental autoimmune neuritis (EAN) models is provided. Originally GBS and acute inflammatory demyelinating polyneuropathy were equated, presence of axonal degeneration being attributed to a “bystander” effect. Afterwards, primary axonal GBS forms were reported, designated as acute motor axonal neuropathy/acute motor-sensory axonal neuropathy. Revision of the first pathological description of axonal GBS indicates the coexistence of active axonal degeneration and demyelination in spinal roots, and pure Wallerian-like degeneration in peripheral nerve trunks. Nerve conduction studies are essential for syndrome subtyping, though their sensitivity is scanty in early GBS. Serum markers of axonal degeneration include increased levels of neurofilament light chain and presence of anti-ganglioside reactivity.

References

110 Cites in Article
  1. Pieter Van Doorn,Liselotte Ruts,Bart Jacobs (2008). Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome.
  2. Hugh Willison,Bart Jacobs,Pieter Van Doorn (2016). Guillain-Barré syndrome.
  3. J Griffin,C Li,T Ho,M Tian,C Gao,P Xue,B Mishu,D Cornblath,C Macko,G Mckhann,A Asbury (1996). Pathology of the motor‐sensory axonal Guillain‐Barré syndrome.
  4. Satoshi Kuwabara,Nobuhiro Yuki (2013). Axonal Guillain-Barré syndrome: concepts and controversies.
  5. Bianca Van Den Berg,Christa Walgaard,Judith Drenthen,Christiaan Fokke,Bart Jacobs,Pieter Van Doorn (2014). Guillain–Barré syndrome: pathogenesis, diagnosis, treatment and prognosis.
  6. J Goodfellow,H Willison (2016). Guillain-Barré syndrome: a century of progress.
  7. A Doets,C Verboon,B Van Den Berg,T Harbo,D Cornblath,H Willison,Z Islam,S Attarian,F Barroso,K Bateman,L Benedetti,P Van Den Bergh,C Casasnovas,G Cavaletti,G Chavada,K Claeys,E Dardiotis,A Davidson,P Van Doorn,T Feasby,G Galassi,K Gorson,H Hartung,S Hsieh,Rac Hughes,I Illa,B Islam,S Kusunoki,S Kuwabara,H Lehmann,Jal Miller,Q Mohammad,S Monges,Nobile Orazio,E Pardo,J Pereon,Y Rinaldi,S Querol,L Reddel,S Reisin,R Shahrizaila,N Sindrup,S Waqar,W Jacobs,B (2018). Regional variation of Guillain-Barré syndrome.
  8. G Sobue,M Li,S Terao,S Aoki,M Ichimura,T Ieda,M Doyu,T Yasuda,Y Hashizume,T Mitsuma (1997). Axonal pathology in Japanese Guillain-Barré syndrome: a study of 15 autopsied cases.
  9. Luana Benedetti,Chiara Briani,Alessandro Beronio,Federico Massa,Elisa Giorli,Cinzia Sani,Paola Delia,Stefania Artioli,Maria Sormani,Antonio Mannironi,Antonio Tartaglione,Giovanni Mancardi (2019). Increased incidence of axonal Guillain‐Barré syndrome in La Spezia area of Italy: A 13‐year follow‐up study.
  10. M Sedano,P Orizaola,E Gallardo,A García,A Pelayo-Negro,P Sánchez-Juan,J Infante,J Berciano (2019). A unicenter, prospective study of Guillain-Barré syndrome in Spain.
  11. José Berciano,María Sedano,Ana Pelayo-Negro,Antonio García,Pedro Orizaola,Elena Gallardo,Miguel Lafarga,María Berciano,Bart Jacobs (2017). Proximal nerve lesions in early Guillain–Barré syndrome: implications for pathogenesis and disease classification.
  12. Antonino Uncini,Luigi Ippoliti,Nortina Shahrizaila,Yukari Sekiguchi,Satoshi Kuwabara (2017). Optimizing the electrodiagnostic accuracy in Guillain-Barré syndrome subtypes: Criteria sets and sparse linear discriminant analysis.
  13. Gyl Midroni,Juan Bilbao (1985). Amyloid Neuropathy.
  14. R King (1999). Atlas of nerve pathology.
  15. P Altmann,De Simoni,D Kaider,A Ludwig,B Rath,J Leutmezer,F Zimprich,F Hoeftberger,R Lunn,M Heslegrave,A Berger,T Zetterberg,H Rommer,P (2020). Increased serum neurofilament light chain concentration indicates poor outcome in Guillain-Barré syndrome.
  16. B Soliven (2014). Animal models of autoimmune neuropathy.
  17. James Albers,Peter Donofrio,Timothy Mcgonagle (1985). Sequential electrodiagnostic abnormalities in acute inflammatory demyelinating polyradiculoneuropathy.
  18. R Madrid,H Wiśniewski (1978). Peripheral nervous system pathology in relapsing experimental allergic encephalomyelitis.
  19. Rhm King,P Thomas,J Pollard (1977). AXONAL AND DORSAL ROOT GANGLION CELL CHANGES IN EXPERIMENTAL ALLERGIC NEURITIS.
  20. G Said,K Saida,T Saida,A Asbury (1981). Axonal lesions in acute experimental demyelination: a sequential teased nerve fiber study.
  21. Arthur Asbury,David Cornblath (1990). Assessment of current diagnostic criteria for Guillain-Barr� syndrome.
  22. T Ho,B Mishu,C Li,C Gao,D Cornblath,J Griffin,A Asbury,M Blaser,G Mckhann (1995). Guillain-Barré syndrome in northern China Relationship to <i>Campylobacter jejuni</i> infection and anti-glycolipid antibodies.
  23. R Hadden,D Cornblath,R Hughes,J Zielasek,H Hartung,K Toyka,A Swan (1998). Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group.
  24. Maria Albertí,Agustí Alentorn,Sergio Martínez‐yelamos,Juan Martínez‐matos,Monica Povedano,Jordi Montero,Carlos Casasnovas (2011). Very early electrodiagnostic findings in Guillain‐Barré syndrome.
  25. José Berciano,Pedro Orizaola,Elena Gallardo,Ana Pelayo-Negro,Pascual Sánchez-Juan,Jon Infante,María Sedano (2020). Very early Guillain-Barré syndrome: A clinical-electrophysiological and ultrasonographic study.
  26. Yuqin Ye,Dan Zhu,Lingyun Liu,Keren Wang,Keke Huang,Changmin Hou (2014). Electrophysiological measurement at Erb’s point during the early stage of Guillain-Barré syndrome.
  27. Ç Temuçin,G Nurlu (2011). Measurement of motor root conduction time at the early stage of Guillain–Barre syndrome.
  28. Kurt Incesu,T Secil,Y Tokucoglu,F Gurgor,N Özdemirkiran,T Akhan,G Ertekin,C (2013). Diagnostic value of lumbar root stimulation at the early stage of Guillain-Barré syndrome.
  29. A Sevy,A Grapperon,Salort Campana,E Delmont,E Attarian,S (2018). Detection of proximal conduction blocks using a triple stimulation technique improves the early diagnosis of Guillain-Barré syndrome.
  30. Kenneth Gorson,Allan Ropper,Mary Muriello,Richard Blair (1996). Prospective evaluation of MRI lumbosacral nerve root enhancement in acute Guillain-Barre syndrome.
  31. W Byun,W Park,B Park,S Ahn,M Hwang,J Chang (1998). Guillain-Barré syndrome: MR imaging findings of the spine in eight patients..
  32. Ali Yikilmaz,Selim Doganay,Hakan Gumus,Huseyin Per,Sefer Kumandas,Abdulhakim Coskun (2010). Magnetic resonance imaging of childhood Guillain–Barre syndrome.
  33. Elena Gallardo,María Sedano,Pedro Orizaola,Pascual Sánchez-Juan,Andrea González-Suárez,Antonio García,Nuria Terán-Villagrá,María Ruiz-Soto,Rosa Álvaro,María Berciano,Miguel Lafarga,José Berciano (2015). Spinal nerve involvement in early Guillain–Barré syndrome: A clinico-electrophysiological, ultrasonographic and pathological study.
  34. José Berciano,Francisco Coria,Fernando Montón,Jesús Calleja,Javier Figols,Miguel Lafarga (1993). Axonal form of Guillain–Barré syndrome: Evidence for macrophage‐associated demyelination.
  35. G Mckhann,D Cornblath,J Griffin,T Ho,C Li,Z Jiang,H Wu,G Zhaori,Y Liu,L Jou,T Liu,C Gao,J Mao,M Blaser,B Mishu,A Asbury (1993). Acute motor axonal neuropathy: A frequent cause of acute flaccid paralysis in China.
  36. J Griffin,C Li,T Ho,P Xue,C Macko,C Gao,C Yang,M Tian,B Mishu,D Cornblath,G Mckhann,A Asbury (1995). Guillain-Barré syndrome in northern China: The spectrum of neuropathological changes in clinically defined cases.
  37. Elena Gallardo,Yu-Ichi Noto,Neil Simon (2015). Ultrasound in the diagnosis of peripheral neuropathy: structure meets function in the neuromuscular clinic.
  38. Alexander Grimm,Bernhard Décard,Axel Schramm,Anne-Katrin Pröbstel,Maria Rasenack,Hubertus Axer,Peter Fuhr (2016). Ultrasound and electrophysiologic findings in patients with Guillain–Barré syndrome at disease onset and over a period of six months.
  39. G Guillain,J Barré,A Strohl (1916). Sur un syndrome de radiculo-névrite avec hyperalbuminose du liquide céphalo-rachidien sans réaction cellulaire. Remarques sur les caractères cliniques et graphiques des réflexes tendineux.
  40. W Krücke (1955). Die primär-entzündliche Polyneuritis unbekannter Ursache.
  41. Arthur Asbury,Barry Arnason,Raymond Adams (1969). THE INFLAMMATORY LESION IN IDIOPATHIC POLYNEURITIS.
  42. Henryk Wiśniewski,R Terry,J Whitaker,S Cook,P Dowling (1969). Landry-Guillain-Barré Syndrome.
  43. S Carpenter (1972). An ultrastructural study of an acute fatal case of the Guillain-Barré syndrome.
  44. J Prineas (1972). Acute idiopathic polyneuritis. An electron microscope study.
  45. Webb Haymaker,James Kernohan (1949). THE LANDRY-GUILLAIN-BARR?? SYNDROME.
  46. C Brechenmacher,C Vital,C Deminiere,L Laurentjoye,Y Castaing,G Gbikpi-Benissan,J Cardinaud,J Favarel-Garrigues (1987). Guillain-Barré syndrome: an ultrastructural study of peripheral nerve in 65 patients.
  47. T Feasby,J Gilbert,W Brown,C Bolton,A Hahn,W Koopman,D Zochodne (1986). AN ACUTE AXONAL FORM OF GUILLAIN-BARRÉE POLYNEUROPATHY.
  48. P Thomas (1992). The Guillain-Barré syndrome: no longer a simple concept.
  49. W Triggs,D Cros,S Gominak,G Zuniga,A Beric,B Shahani,A Ropper,S Roongta (1992). MOTOR NERVE INEXCITABILITY IN GUILLAIN-BARRÉ SYNDROME.
  50. D Cros,W Triggs (1994). There are no neurophysiologic features characteristic of "axonal" Guillain-Barré syndrome.
  51. Nobuhiro Yuki (1994). Pathogenesis of axonal Guillain–Barré syndrome: Hypothesis.
  52. T Feasby,A Hahn,W Brown,C Bolton,J Gilbert,W Koopman (1993). Severe axonal degeneration in acute Guillain-Barré syndrome: Evidence of two different mechanisms?.
  53. Thomas Feasby (1994). Axonal Guillain–Barré syndrome.
  54. T Feasby (2016). GBS100 Celebrating a centenary of progress in Guillain-Barré syndrome.
  55. Nobuhiro Yuki,Hiide Yoshino,Shuzo Sato,Tadashi Miyatake (1990). Acute axonal polyneuropathy associated with anti‐GM <sub>1</sub> antibodies following <i>Campylobacter enteritis</i>.
  56. N Gregson,D Jones,P Thomas,H Willison (1991). Acute motor neuropathy with antibodies to GM1 ganglioside.
  57. G Mckhann,D Cornblath,T Ho,J Griffin,C Li,A Bai,H Wu,Q Yei,W Zhang,Z Zhaori,Z Jiang,A Asbury (1991). Clinical and electrophysiological aspects of acute paralytic disease of children and young adults in northern China.
  58. Susan Hall,Richard Hughes,Penny Atkinson,Ian Mccoll,Andrew Gale (1992). Motor nerve biopsy in severe Guillain‐Barré syndrome.
  59. T Ho,S Hsieh,I Nachamkin,H Willison,K Sheikh,J Kiehlbauch,K Flanigan,J Mcarthur,D Cornblath,G Mckhann,J Griffin (1997). Motor nerve terminal degeneration provides a potential mechanism for rapid recovery in acute motor axonal neuropathy after Campylobacter infection.
  60. G Mckhann,T Ho (2016). GBS100 Celebrating a centenary of progress in Guillain-Barré syndrome.
  61. J Griffin,C Li,C Macko,T Ho,S-T Hsieh,P Xue,F Wang,D Cornblath,G Mckhann,A Asbury (1996). Early nodal changes in the acute motor axonal neuropathy pattern of the Guillain-Barré syndrome.
  62. Charlene Hafer‐macko,Sung‐tsang Hsieh,Tony Ho,Kazim Sheikh,David Cornblath,Chun Li,Guy Mckhann,Arthur Asbury,John Griffin (1996). Acute motor axonal neuropathy: An antibody‐mediated attack on axolemma.
  63. C Hafer-Macko,K Sheikh,C Li,T Ho,D Cornblath,G Mckhann,A Asbury,J Griffin (1996). Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy.
  64. Hugh Willison (2012). The translation of the pathological findings described in humans to experimental models of acute motor axonal neuropathy.
  65. Antonino Uncini,Keiichiro Susuki,Nobuhiro Yuki (2013). Nodo-paranodopathy: Beyond the demyelinating and axonal classification in anti-ganglioside antibody-mediated neuropathies.
  66. Vinay Chaudhry,David Cornblath (1992). Wallerian degeneration in human nerves: Serial electrophysiological studies.
  67. José Berciano,Javier Figols,Antonio García,Ester Calle,Isabel Illa,Miguel Lafarga,María Berciano (1997). Fulminant Guillain–Barré Syndrome with universal inexcitability of peripheral nerves: A clinicopathological study.
  68. T Kanda,H Hayashi,H Tanabe,T Tsubaki,M Oda (1989). A fulminant case of Guillain-Barre syndrome: topographic and fibre size related analysis of demyelinating changes..
  69. J Berciano,A García,J Figols,R Muñoz,M Berciano,M Lafarga (2000). Perineurium contributes to axonal damage in acute inflammatory demyelinating polyneuropathy.
  70. José Berciano,Antonio García,Nuria Villagrá,Félix González,César Ramón,Isabel Illa,María Berciano,Miguel Lafarga (2009). Severe Guillain‐Barré syndrome: sorting out the pathological hallmark in an electrophysiological axonal case.
  71. John Goodfellow,Hugh Willison (2018). Gangliosides and Autoimmune Peripheral Nerve Diseases.
  72. Byron Waksman,Raymond Adams (1955). ALLERGIC NEURITIS: AN EXPERIMENTAL DISEASE OF RABBITS INDUCED BY THE INJECTION OF PERIPHERAL NERVOUS TISSUE AND ADJUVANTS.
  73. S Izumo,C Linington,H Wekerle,R Meyermann (1985). Morphologic study on experimental allergic neuritis mediated by T cell line specific for bovine P 2 protein in Lewis rats.
  74. Kurt Heininger,Guido Stoll,Christopher Linington,Klaus Toyka,Hartmut Wekerle (1986). Conduction failure and nerve conduction slowing in experimental allergic neuritis induced by P<sub>2</sub>‐specific T‐cell lines.
  75. A Hahn,T Feasby,L Wilkie,D Lovgren (1991). P2-peptide induced experimental allergic neuritis: a model to study axonal degeneration.
  76. A Hahn,T Feasby,L Wilkie,D Lovgren (1988). P2-peptide induced experimental allergic neuritis: a model to study axonal degeneration.
  77. H Powell,S Braheny,R Myers,M Rodriguez,P Lampert (1983). Early changes in experimental allergic neuritis.
  78. H Powell,R Myers,A Mizisin,T Olee,S Brostoff (1991). Response of the axon and barrier endothelium to experimental allergic neuritis induced by autoreactive T cell lines.
  79. Philip Mcmanis,Phillip Low,Terrence Lagerlund (1993). Nerve Blood Flow and Microenvironment.
  80. R Hadden,N Gregson,R Gold,K Smith,R Hughes (2002). Accumulation of immunoglobulin across the ‘blood–nerve barrier’ in spinal roots in adoptive transfer experimental autoimmune neuritis.
  81. S Kusunoki (2016). GBS100 Celebrating a centenary of progress in Guillain-Barré syndrome.
  82. Nobuhiro Yuki,Mitsunori Yamada,Michiaki Koga,Masaaki Odaka,Keiichiro Susuki,Yumi Tagawa,Shuichi Ueda,Takeshi Kasama,Akio Ohnishi,Shintaro Hayashi,Hitoshi Takahashi,Mikiko Kamijo,Koichi Hirata (2001). Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside.
  83. I Nachamkin (2002). Rabbit model of Guillain-Barré syndrome.
  84. A Moyano,R Comín,R Lardone,M Alaniz,R Theaux,F Irazoqui,G Nores (2008). Validation of a rabbit model of neuropathy induced by immunization with gangliosides.
  85. Keiichiro Susuki,Yukihiro Nishimoto,Mitsunori Yamada,Masayuki Baba,Shuichi Ueda,Koichi Hirata,Nobuhiro Yuki (2003). Acute motor axonal neuropathy rabbit model: Immune attack on nerve root axons.
  86. Keiichiro Susuki,Matthew Rasband,Koujiro Tohyama,Katsura Koibuchi,Saori Okamoto,Kei Funakoshi,Koichi Hirata,Hiroko Baba,Nobuhiro Yuki (2007). Anti-GM1 Antibodies Cause Complement-Mediated Disruption of Sodium Channel Clusters in Peripheral Motor Nerve Fibers.
  87. Nobuhiro Yuki,Keiichiro Susuki,Michiaki Koga,Yukihiro Nishimoto,Masaaki Odaka,Koichi Hirata,Kyoji Taguchi,Tadashi Miyatake,Koichi Furukawa,Tetsuji Kobata,Mitsunori Yamada (2004). Carbohydrate mimicry between human ganglioside GM1 and <i>Campylobacter jejuni</i> lipooligosaccharide causes Guillain–Barré syndrome.
  88. C Li,P Xue,W Tian,R Liu,C Yang (1996). Experimental Campylobacter jejuni infection in the chicken: an animal model of axonal Guillain-Barré syndrome.
  89. G O'hanlon,P Humphreys,R Goldman,S Halstead,R Bullens,J Plomp,Y Ushkaryov,H Willison (2003). Calpain inhibitors protect against axonal degeneration in a model of anti-ganglioside antibody-mediated motor nerve terminal injury.
  90. Jaap Plomp,Hugh Willison (2009). Pathophysiological actions of neuropathy‐related anti‐ganglioside antibodies at the neuromuscular junction.
  91. Frank Spaans,Jan‐willem Vredeveld,Humphrey Morré,Bart Jacobs,Marc De Baets (2003). Dysfunction at the motor end‐plate and axon membrane in Guillain–Barré syndrome: A single‐fiber EMG study.
  92. S Kuwabara,N Kokubun,S Misawa,K Kanai,S Isose,K Shibuya,Y Noto,M Mori,Y Sekiguchi,S Nasu,Y Fujimaki,K Hirata,N Yuki (2011). Neuromuscular transmission is not impaired in axonal Guillain-Barre syndrome.
  93. William Brown,Thomas Feasby,Angelika Hahn (1993). Electrophysiological changes in the acute “axonal” form of Guillain–Barre syndrome.
  94. Madeleine Cunningham,Gavin Meehan,Sophie Robinson,Denggao Yao,Rhona Mcgonigal,Hugh Willison (2020). Perisynaptic Schwann cells phagocytose nerve terminal debris in a mouse model of <scp>Guillain‐Barré</scp> syndrome.
  95. Jan Korthals,Maria Korthals,Henryk Wisniewski (1978). Peripheral nerve ischemia: Part 2. Accumulation of organelles.
  96. Hitoshi Nukada,Peter Dyck (1987). Acute ischemia causes axonal stasis, swelling, attenuation, and secondary demyelination.
  97. Peter Spencer,P Thomas (1974). Ultrastructural studies of the dying-back process II. The sequestration and removal by Schwann cells and oligodendrocytes of organelles from normal and diseased axons.
  98. Yngve Olsson (1968). Topographical differences in the vascular permeability of the peripheral nervous system.
  99. T ; Kanda,Y Olsson (1975). Biology of the blood–nerve barrier and its alteration in immune mediated neuropathies.
  100. C-H Berthold,John Fraher,Rhm King,Martin Rydmark (2005). Microscopic Anatomy of the Peripheral Nervous System.
  101. L Gaetani,K Blennow,P Calabresi,Di Filippo,M Parnetti,L Zetterberg,H (2019). Neurofilament light chain as a biomarker in neurological disorders.
  102. Susan Halstead,Peter Humphreys,John Goodfellow,Eric Wagner,Richard Smith,Hugh Willison (2005). Complement inhibition abrogates nerve terminal injury in Miller Fisher syndrome.
  103. Rhona Mcgonigal,Edward Rowan,Kay Greenshields,Susan Halstead,Peter Humphreys,Russell Rother,Koichi Furukawa,Hugh Willison (2010). Anti-GD1a antibodies activate complement and calpain to injure distal motor nodes of Ranvier in mice.
  104. Peter Hillmen,Neal Young,Jörg Schubert,Robert Brodsky,Gerard Socié,Petra Muus,Alexander Röth,Jeffrey Szer,Modupe Elebute,Ryotaro Nakamura,Paul Browne,Antonio Risitano,Anita Hill,Hubert Schrezenmeier,Chieh-Lin Fu,Jaroslaw Maciejewski,Scott Rollins,Christopher Mojcik,Russell Rother,Lucio Luzzatto (2006). The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria.
  105. Alex Doets,Richard Hughes,Ruth Brassington,Robert Hadden,Jane Pritchard (2020). Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome.
  106. Henry Powell,Robert Myers (1996). The axon in guillain‐Barré syndrome: Immune target or innocent bystander?;.
  107. Arthur Asbury,Howard Fields (1984). Pain due to peripheral nerve damage.
  108. D Moulin,N Hagen,T Feasby,R Amireh,A Hahn (1997). Pain in Guillain-Barre syndrome.
  109. Liselotte Ruts,Roberto Rico,Rinske Van Koningsveld,Juan Botero,Jan Meulstee,Izzy Gerstenbluth,Ingemar Merkies,Pieter Van Doorn (2008). Pain accompanies pure motor Guillain‐Barré syndrome.
  110. Liselotte Ruts,Rinske Van Koningsveld,Bart Jacobs,Pieter Van Doorn (2007). Determination of pain and response to methylprednisolone in Guillain-Barré syndrome.

Funding

No external funding was declared for this work.

Conflict of Interest

The authors declare no conflict of interest.

Ethical Approval

No ethics committee approval was required for this article type.

Data Availability

Not applicable for this article.

How to Cite This Article

Jose Berciano. 2020. \u201cAxonal Degeneration in Guillain–Barré Syndrome: A Reappraisal\u201d. Global Journal of Medical Research - A: Neurology & Nervous System GJMR-A Volume 20 (GJMR Volume 20 Issue A3): .

Download Citation

Journal Specifications

Crossref Journal DOI 10.17406/gjmra

Print ISSN 0975-5888

e-ISSN 2249-4618

Keywords
Classification
GJMR-A Classification: NLMC Code: WL 140
Version of record

v1.2

Issue date

October 24, 2020

Language
en
Experiance in AR

Explore published articles in an immersive Augmented Reality environment. Our platform converts research papers into interactive 3D books, allowing readers to view and interact with content using AR and VR compatible devices.

Read in 3D

Your published article is automatically converted into a realistic 3D book. Flip through pages and read research papers in a more engaging and interactive format.

Article Matrices
Total Views: 2179
Total Downloads: 1032
2026 Trends
Related Research

Published Article

The aim of this review was to analyse the pathophysiology of axonal degeneration in Guillain-Barré syndrome (GBS) with emphasis on early stages (≤ 10 days after onset). An overview of experimental autoimmune neuritis (EAN) models is provided. Originally GBS and acute inflammatory demyelinating polyneuropathy were equated, presence of axonal degeneration being attributed to a “bystander” effect. Afterwards, primary axonal GBS forms were reported, designated as acute motor axonal neuropathy/acute motor-sensory axonal neuropathy. Revision of the first pathological description of axonal GBS indicates the coexistence of active axonal degeneration and demyelination in spinal roots, and pure Wallerian-like degeneration in peripheral nerve trunks. Nerve conduction studies are essential for syndrome subtyping, though their sensitivity is scanty in early GBS. Serum markers of axonal degeneration include increased levels of neurofilament light chain and presence of anti-ganglioside reactivity.

Our website is actively being updated, and changes may occur frequently. Please clear your browser cache if needed. For feedback or error reporting, please email [email protected]

Request Access

Please fill out the form below to request access to this research paper. Your request will be reviewed by the editorial or author team.
X

Quote and Order Details

Contact Person

Invoice Address

Notes or Comments

This is the heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

High-quality academic research articles on global topics and journals.

Axonal Degeneration in Guillain–Barré Syndrome: A Reappraisal

Jose Berciano
Jose Berciano Universidad de Cantabria

Research Journals